Ledipasvir/sofosbuvir
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ledipasvir/sofosbuvir, sold under the trade name Harvoni among others, is a medication used to treat hepatitis C. It is a fixed-dose combination of ledipasvir and sofosbuvir. Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. Some evidence also supports use in HCV genotype 3 and 4.
It is taken daily by mouth for 8–24 weeks. It is generally well tolerated. Common side effects include muscle pains, headache, nausea, rash, and cough.
It is unclear if use in pregnancy is safe for the baby. Ledipasvir works by decreasing the activity of NS5A and sofosbuvir works by decreasing the activity of NS5B polymerase. Ledipasvir/sofosbuvir was approved for medical use in the United States, in the European Union, and in Canada in 2014.
It is on the World Health Organization's List of Essential Medicines.
Medical uses
Cure rates are 94% to 99% in people infected with genotype 1 (46% of HCV cases). It has also been evaluated for the treatment of infection with other hepatitis C genotypes, and has shown promising results in genotypes 3 and 4 (making up 30% and less than 22% of HCV cases respectively).
Society and culture
One manufacturer is Gilead Sciences.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1313798403 under CC BY-SA 4.0; modifications have been made.